• News
  • BioTech

Isis earns $3M milestone payment

Carlsbad-based Isis Pharmaceuticals (Nasdaq: ISIS) has earned a $3 million milestone payment from GlaxoSmithKline (NYSE: GSK) related to starting a natural history study that would support one of the programs in their alliance to develop treatments for rare and infectious diseases.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!